To validate in a real-life setting the lower threshold of platelet for the World Health Organization WHO 2008/2016 diagnosis of essential thrombocythemia, 162 patients were retrospectively analyzed according to platelet (PLT) levels at diagnosis (group A, PLT >= 600 x 10(9)/L and group B, PLT >= 450 < 600 x 10(9)/L). After a median follow-up of 42.4 months, thrombotic events and 5-year overall survival were similar between the 2 groups. Our data confirmed the usefulness of the 2008/2016 World Health Organization diagnostic criteria. Background: According to 2008/2016 classification of the World Health Organization (WHO), a platelet (PLT) count >= 450 x 10(9)/L, reduced from the previously published WHO 2001 indicated level 600 x 10(9)/L, was considered the new PLT threshold for the diagnosis of essential thrombocythemia (ET). Patients and Methods: To validate this important diagnostic change in a setting of current clinical practice, we retrospectively analyzed clinical and hematologic features at diagnosis and during follow-up of 162 patients with ET, diagnosed in our center from January 2008 to December 2017. We subdivided patients according to PLT value at baseline into Group A (PLT > 600 x 10(9)/L) (124 patients; 76.5\%) and Group B (PLT >= 450 x 10(9)/L < 600 x 10(9)/L) (38 patients; 23.5\%). Results: Among clinical features, only the median value of leukocytes (P < .001) was significantly higher in Group A. Cytostatic treatment was administered in 103 patients, with a significantly higher rate in patients of group A (P < .001). After a median follow-up of 42.4 months (interquartile range, 22.1-70.6 months), 8 thrombotic events were recorded in the entire cohort, without differences between the 2 groups (P- .336). The 5-year overall survival (OS) of the entire cohort was 96.9\% (95\% confidence interval, 92.6\%-100\%), without differences between the 2 groups (P - .255). Conclusions: Our data indicate a substantial homogeneity among patients with ET regardless of the PLT count at diagnosis, thus confirming the usefulness of the 2008/2016 WHO diagnostic criteria. (C) 2020 Elsevier Inc. All rights reserved.
Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of 2001 WHO Versus 2008/2016 WHO Criteria in a Large Single-center Cohort / Ranieri, Sofia Chiatamone; Arleo, Maria Antonietta; Trasarti, Stefania; Bizzoni, Luisa; Carmosino, Ida; De Luca, Maria Lucia; Mohamed, Sara; Mariggio, Elena; Scalzulli, Emilia; Rosati, Serena; De Benedittis, Daniela; Colafigli, Gioia; Pepe, Sara; Molica, Matteo; Scamuffa, Maria Cristina; Di Prima, Alessio; Ferretti, Antonietta; Baldacci, Emilia; Mancini, Marco; Santoro, Cristina; Vignetti, Marco; Breccia, Massimo; Latagliata, Roberto. - In: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. - ISSN 2152-2650. - 21:4(2021), pp. 328-333. [10.1016/j.clml.2020.11.003]
Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of 2001 WHO Versus 2008/2016 WHO Criteria in a Large Single-center Cohort
Bizzoni, Luisa;Carmosino, Ida;Scalzulli, Emilia;Colafigli, Gioia;Pepe, Sara;Molica, Matteo;Mancini, Marco;Santoro, Cristina;Vignetti, Marco;Breccia, Massimo;
2021
Abstract
To validate in a real-life setting the lower threshold of platelet for the World Health Organization WHO 2008/2016 diagnosis of essential thrombocythemia, 162 patients were retrospectively analyzed according to platelet (PLT) levels at diagnosis (group A, PLT >= 600 x 10(9)/L and group B, PLT >= 450 < 600 x 10(9)/L). After a median follow-up of 42.4 months, thrombotic events and 5-year overall survival were similar between the 2 groups. Our data confirmed the usefulness of the 2008/2016 World Health Organization diagnostic criteria. Background: According to 2008/2016 classification of the World Health Organization (WHO), a platelet (PLT) count >= 450 x 10(9)/L, reduced from the previously published WHO 2001 indicated level 600 x 10(9)/L, was considered the new PLT threshold for the diagnosis of essential thrombocythemia (ET). Patients and Methods: To validate this important diagnostic change in a setting of current clinical practice, we retrospectively analyzed clinical and hematologic features at diagnosis and during follow-up of 162 patients with ET, diagnosed in our center from January 2008 to December 2017. We subdivided patients according to PLT value at baseline into Group A (PLT > 600 x 10(9)/L) (124 patients; 76.5\%) and Group B (PLT >= 450 x 10(9)/L < 600 x 10(9)/L) (38 patients; 23.5\%). Results: Among clinical features, only the median value of leukocytes (P < .001) was significantly higher in Group A. Cytostatic treatment was administered in 103 patients, with a significantly higher rate in patients of group A (P < .001). After a median follow-up of 42.4 months (interquartile range, 22.1-70.6 months), 8 thrombotic events were recorded in the entire cohort, without differences between the 2 groups (P- .336). The 5-year overall survival (OS) of the entire cohort was 96.9\% (95\% confidence interval, 92.6\%-100\%), without differences between the 2 groups (P - .255). Conclusions: Our data indicate a substantial homogeneity among patients with ET regardless of the PLT count at diagnosis, thus confirming the usefulness of the 2008/2016 WHO diagnostic criteria. (C) 2020 Elsevier Inc. All rights reserved.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
